Crescent Biopharma, Inc. Common Stock CBIO
i
Market dataready · fetched 2026-11-13T19:11:56.786Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-12-18
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-13T19:07:32.872600653Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-13T19:11:55.780321+00:00
Crescent Biopharma, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 9.97 | 296.8% | 46.7% | |||
| 25Δ | 11.19 | 251.1% | 38.2% | |||
| 30Δ | 12.40 | 206.0% | 29.8% | |||
| 35Δ | 13.16 | 183.0% | 24.9% | |||
| 40Δ | 29.28 | 313.7% | 124.9% | 13.89 | 162.0% | 20.3% |
| 45Δ | 20.86 | 244.8% | 65.2% | 14.61 | 140.9% | 15.7% |
| 50Δ | 17.39 | 205.4% | 41.1% | 15.27 | 126.9% | 12.3% |
| 55Δ | 16.11 | 192.5% | 33.8% | 15.86 | 120.9% | 10.4% |
| 60Δ | 14.84 | 179.7% | 26.4% | 16.45 | 115.0% | 8.5% |
| 65Δ | 13.56 | 166.9% | 19.1% | 17.04 | 109.0% | 6.5% |
| 70Δ | 12.34 | 156.7% | 12.6% | 17.83 | 106.4% | 4.8% |
| 75Δ | 11.42 | 159.1% | 10.1% | 19.35 | 115.8% | 4.0% |
| 80Δ | 10.50 | 161.5% | 7.7% | 20.56 | 116.4% | 3.0% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.97
- IV
- 296.8%
- B/E move
- 46.7%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 11.19
- IV
- 251.1%
- B/E move
- 38.2%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 12.40
- IV
- 206.0%
- B/E move
- 29.8%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 13.16
- IV
- 183.0%
- B/E move
- 24.9%
40Δ
- Pseudo strike
- 29.28
- IV
- 313.7%
- B/E move
- 124.9%
- Pseudo strike
- 13.89
- IV
- 162.0%
- B/E move
- 20.3%
45Δ
- Pseudo strike
- 20.86
- IV
- 244.8%
- B/E move
- 65.2%
- Pseudo strike
- 14.61
- IV
- 140.9%
- B/E move
- 15.7%
50Δ
- Pseudo strike
- 17.39
- IV
- 205.4%
- B/E move
- 41.1%
- Pseudo strike
- 15.27
- IV
- 126.9%
- B/E move
- 12.3%
55Δ
- Pseudo strike
- 16.11
- IV
- 192.5%
- B/E move
- 33.8%
- Pseudo strike
- 15.86
- IV
- 120.9%
- B/E move
- 10.4%
60Δ
- Pseudo strike
- 14.84
- IV
- 179.7%
- B/E move
- 26.4%
- Pseudo strike
- 16.45
- IV
- 115.0%
- B/E move
- 8.5%
65Δ
- Pseudo strike
- 13.56
- IV
- 166.9%
- B/E move
- 19.1%
- Pseudo strike
- 17.04
- IV
- 109.0%
- B/E move
- 6.5%
70Δ
- Pseudo strike
- 12.34
- IV
- 156.7%
- B/E move
- 12.6%
- Pseudo strike
- 17.83
- IV
- 106.4%
- B/E move
- 4.8%
75Δ
- Pseudo strike
- 11.42
- IV
- 159.1%
- B/E move
- 10.1%
- Pseudo strike
- 19.35
- IV
- 115.8%
- B/E move
- 4.0%
80Δ
- Pseudo strike
- 10.50
- IV
- 161.5%
- B/E move
- 7.7%
- Pseudo strike
- 20.56
- IV
- 116.4%
- B/E move
- 3.0%
Options history
Table
| Date | IV (%) |
|---|---|
| 169.86% | |
| 187.29% | |
| 212.03% | |
| 109.61% | |
| 112.57% | |
| 111.49% | |
| 112.82% | |
| 109.83% | |
| 114.08% | |
| 121.90% | |
| 122.87% | |
| 121.57% | |
| 105.98% | |
| 116.13% | |
| 131.08% | |
| 131.37% | |
| 132.08% | |
| 138.74% | |
| 176.55% | |
| 121.77% | |
| 128.81% | |
| 129.51% | |
| 141.05% | |
| 150.58% | |
| 129.88% | |
| 137.87% | |
| 152.88% | |
| 154.28% | |
| 142.95% | |
| 161.03% | |
| 171.16% | |
| 175.82% | |
| 186.67% | |
| 186.20% | |
| 170.99% | |
| 262.66% | |
| 155.41% | |
| 152.23% | |
| 145.72% | |
| 157.22% | |
| 154.00% | |
| 159.01% | |
| 164.80% | |
| 163.90% | |
| 161.95% | |
| 139.82% | |
| 163.36% |
Biotechnology
CCCC
Description unavailable
More →CDXS
Codexis, Inc. discovers, develops and sells biocatalysts. The company is headquartered in Redwood City, California.
More →CELC
Celcuity Inc., a clinical-stage biotechnology company, discovers cancer subtypes and therapeutic options for cancer patients in the United States. The company is headquartered in…
More →CELU
Celularity Inc. is a pioneering biotechnology company focused on regenerative medicine through its innovative cellular products derived from the placenta. The company is advancing…
More →CGEM
Cullinan Management, Inc., a biopharmaceutical company, is focused on developing a line of targeted oncology and immuno-oncology therapies for cancer patients in the United…
More →CGON
CG Oncology, Inc. is a clinical-stage biotechnology firm focused on developing groundbreaking cancer therapies, particularly through its lead product, CG0070, an oncolytic virus…
More →